PGBD4 Inhibitors
PGBD4 inhibitors are chemical compounds designed to specifically target and inhibit the activity of a protein known as PiggyBac Transposable Element Derived 4 (PGBD4). This protein is a member of the piggyBac family of transposases, which are enzymes that facilitate the cutting and pasting of transposable elements within the genome. PGBD4, like other transposases, is able to recognize specific DNA sequences and perform DNA cleavage and reintegration, which can result in the rearrangement of genetic material. The inhibition of PGBD4 is of interest in the field of molecular biology and genetics due to the protein's role in these genomic processes. PGBD4 inhibitors, therefore, are designed to bind to the active site or another critical region of the PGBD4 protein to prevent it from carrying out its normal function, altering the dynamics of genetic rearrangements.
The development and characterization of PGBD4 inhibitors are rooted in the intricate interplay of protein structure and function. By targeting the active site or allosteric sites of PGBD4, these inhibitors can modulate the enzyme's activity. The molecules are typically small, organic compounds that are optimized for high affinity and specificity to the PGBD4 protein. The structure-activity relationship (SAR) of these inhibitors is a critical aspect of their design, with careful consideration given to the chemical groups and their placement within the molecule to maximize interactions with the protein target. Inhibitors may function through a variety of mechanisms, such as competitive inhibition, where the inhibitor competes with the natural substrate or DNA sequence for binding to the protein, or non-competitive inhibition, where the inhibitor binds to a different site on the protein and induces a conformational change that reduces its activity. Understanding the precise molecular interactions between PGBD4 and its inhibitors is essential for the advancement of this class of compounds within the realm of molecular genetics.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor that can alter the chromatin structure, thereby potentially repressing the transcription of certain genes including "Protein Name". Inhibition of histone deacetylase could lead to a reduction in PGBD4 expression if PGBD4 is regulated by acetylation states. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine is a DNA methyltransferase inhibitor that leads to hypomethylation of DNA. Decreased methylation may reduce expression levels of certain genes, potentially including PGBD4 if its expression is epigenetically regulated by methylation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that can downregulate protein synthesis pathways. Since PGBD4 synthesis could be regulated by mTOR pathways, its functional activity might be decreased indirectly by rapamycin through suppression of its synthesis. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that prevents activation of AKT, thereby inhibiting the PI3K/AKT/mTOR pathway. Reduced activity of this pathway may lead to decreased synthesis and activity of PGBD4. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that acts similarly to LY294002, potentially decreasing PGBD4 expression by inhibiting the PI3K/AKT/mTOR signaling pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that disrupts the MAPK/ERK pathway. As a result of this disruption, if PGBD4 is regulated by the MAPK/ERK pathway, its expression and functional activity could be indirectly reduced. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that could interfere with stress response pathways. If PGBD4 is implicated in these pathways, its expression or activity may be decreased by inhibiting p38 MAPK. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which may affect transcription factors and genes regulated by the JNK pathway. If PGBD4 expression is controlled by the JNK pathway, inhibiting JNK could reduce PGBD4 activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, which also disrupts the MAPK/ERK pathway. Through this mechanism, PGBD4 expression and function could be indirectly inhibited if it is regulated by the MAPK/ERK pathway. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor that might influence the cytoskeleton and related signaling pathways. Should PGBD4 be involved in these pathways, its activity could be decreased by the inhibition of ROCK. | ||||||